Ludwig Institute for Cancer Research
62
3
3
44
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
24.2%
15 terminated/withdrawn out of 62 trials
74.6%
-11.9% vs industry average
0%
0 trials in Phase 3/4
116%
51 of 44 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (62)
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Role: collaborator
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
Role: collaborator
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
Role: collaborator
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Role: lead
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Role: collaborator
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Role: collaborator
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Role: lead
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Role: lead
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Role: lead
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
Role: lead
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Role: lead
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Role: lead
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
Role: lead
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Role: lead
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
Role: lead
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Role: lead
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Role: lead
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
Role: lead
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
Role: lead
Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
Role: lead